The US Cystic Fibrosis Foundation has pledged up to $2.3m to Owlstone Medical for the development of a breath test for pseudomonas aeruginosa detection in patients with cystic fibrosis (CF).
Owlstone Medical Develops P.aeruginosa Breath Test For Cystic Fibrosis Patients
Cystic Fibrosis Foundation Pledges Up To $2.3m For Test Development
Cambridge, UK-based breath biopsy company Owlstone Medical will apply its volatile organic compound analysis platform in an attempt to develop a test for the identification and monitoring of pseudomonas aeruginosa in patients with cystic fibrosis.
